GenMark Diagnostics

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its sensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

Amyris

Clean Energy Fuels

Himax Tech

Inovio Pharmaceuticals

Sunopta

United Microelectronics

Some of the best cheap stocks for 2021 include chipmakers like UMC stock and pharmaceuticals in the COVID-19 vaccine race such as INO stock. The post 7 Great Cheap Stocks To Buy For Solid Growth In 2021 appeared first on InvestorPlace.

7 Great Cheap Stocks To Buy For Solid Growth In 2021

CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020.

GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020

Fulgent Genetics

Natera

Aspira Women’s Health 

Co-Diagnostics

These winners are positioned for gains even after COVID.

These Were the 5 Best Diagnostics Stocks of 2020

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.

GenMark Diagnostics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTech & Diagnostics Forum.

GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q3 2020 Results - Earnings Call Transcript

CARLSBAD, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September 30, 2020.

GenMark Diagnostics Reports Third Quarter 2020 Results

GenMark Diagnostics (GNMK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GenMark Diagnostics (GNMK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CARLSBAD, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, October 28, 2020. Management will hold a conference call to review the company's financial performance starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.

GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020

GenMark Diagnostics just received emergency approval for its coronavirus test panel. GNMK stock is soaring as a result.

GNMK Stock: Why GenMark Diagnostics Is Soaring Today

Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season

GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA

Tests that can screen for the flu, the coronavirus and other pathogens could be crucial in combating Covid-19 and influenza this winter, public health specialists say.

FDA grants emergency clearance for GenMark test that screens for the flu, coronavirus and other viruses

Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth

GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020

Investors need to pay close attention to GenMark Diagnostics (GNMK) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in GenMark Diagnostics (GNMK) Stock?

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens    helps health care professionals prepare for flu season

GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

QuidelOrtho Corp

Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test.

COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test

Luminex

OPKO Health

Why Co-Diagnostics, GenMark, Luminex, and Opko Stocks Are Sinking Today

Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity

GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor® SARS-CoV-2 Test

AbbVie

Eastman Chemical

Enbridge

Enterprise Products Partners

Altria

Microsoft

Prudential Financial

Teladoc

Investing For The Long Run: Navigating A Bifurcated Market

Most medical diagnostic and research companies tend not to be involved in the COVID-19 virus vaccine race, but entries who are need tools to speed their pace.

GenMark: Near-Term Capital Gain Prospects From COVID-19 Testing Race

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q2 2020 Results - Earnings Call Transcript

Shares of GenMark Diagnostics (NASDAQ:GNMK) moved lower by 6.81% in after-market trading after the company reported Q2 results.

Recap: GenMark Diagnostics Q2 Earnings

CARLSBAD, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020.

GenMark Diagnostics Reports Second Quarter 2020 Results

Is  (GNMK) Outperforming Other Medical Stocks This Year?

Has GenMark Diagnostics (GNMK) Outpaced Other Medical Stocks This Year?

CARLSBAD, Calif., July  21, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on Tuesday, August 4, 2020. Management will hold a conference call to review the company's financial performance starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.

News for GenMark Diagnostics Stock (GNMK)